Compare OPY & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPY | ABCL |
|---|---|---|
| Founded | 1881 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 956.2M | 1.1B |
| IPO Year | 1996 | 2020 |
| Metric | OPY | ABCL |
|---|---|---|
| Price | $105.39 | $3.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 44.7K | ★ 2.4M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.69% | N/A |
| EPS Growth | ★ 104.71 | 10.91 |
| EPS | ★ 13.04 | N/A |
| Revenue | ★ $1,638,071,000.00 | $75,128,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $23.96 |
| P/E Ratio | $8.01 | ★ N/A |
| Revenue Growth | 14.35 | ★ 160.56 |
| 52 Week Low | $53.99 | $1.94 |
| 52 Week High | $105.38 | $6.52 |
| Indicator | OPY | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 79.70 | 53.95 |
| Support Level | $82.75 | $3.37 |
| Resistance Level | N/A | $3.80 |
| Average True Range (ATR) | 3.40 | 0.15 |
| MACD | 1.98 | 0.01 |
| Stochastic Oscillator | 97.07 | 67.78 |
Oppenheimer Holdings Inc conducts activities in the securities industry. The company is involved in retail securities brokerage, investment banking (both corporate and public finance), institutional sales and trading, market-making, research, trust services, and investment advisory and asset management services. The company has two segments: Wealth Management, and Capital Markets. IT generates maximum revenue from Wealth Management Segment which includes commissions and fee income earned on assets under management (AUM), net interest earnings on client margin loans and cash balances, fees from money market funds, custodian fees and other activities. The company generates the majority of its revenue from the Americas, with the rest from Europe, the Middle East, and Asia.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.